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Abstract
Purpose Pancreatic cancer (PC) is a disease with bad
prognosis. It is usually diagnosed at advanced stages and its
treatment is complex. The aim of this consensus document
was to provide recommendations by experts that would
ameliorate PC diagnosis, reduce the time to treatment, and
optimize PC management by interdisciplinary teams.
Methods As a consensus method, we followed the modi-
fied Delphi methodology. A scientific committee of experts
provided 40 statements that were submitted in two rounds
to a panel of 87 specialists of 12 scientific societies.
Results Agreement was reached for 39 of the 40 proposed
statements (97.5%).
Conclusions Although a screening of the asymptomatic
population is not a feasible option, special attention to
potential symptoms during primary care could ameliorate
early diagnostic. It is especially important to decrease the
period until diagnostic tests are performed. This consensus
could improve survival in PC patients by decreasing the
time to diagnose and time to treatment and by the imple-
mentation of multidisciplinary teams.
Keywords Pancreatic neoplasms  Delphi technique 
Interdisciplinary communication  Early detection of
cancer  Time-to-treatment
Introduction
Pancreatic cancer (PC) is a disease with a poor prognosis.
The median overall survival from diagnosis is 4.6 months
in patients with metastatic disease and 10–12 months after
resection [1]. Unlike other cancers, which have improved
survival in recent decades [2], the prognosis of this disease
has not improved in the past 20 years, and its incidence and
high mortality have remained practically constant [3]. PC
is the fourth most common tumor in Europe both in men,
after lung, colorectal, and prostate cancer, as in women,
after breast, colorectal, and lung cancer [2].
Most patients with CP develop a locally advanced or
metastatic disease during an asymptomatic phase of the
tumor [3]. The initial symptoms are non-specific, which
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may lengthen the diagnostic process and contribute to the
fact that most patients are not diagnosed until advanced
stages of the disease (up to 80–85%), when the tumor has
metastasized [4]. Surgical resection is possible in only
15–20% of patients, but even with surgical treatment, sur-
vival at 5 years is approximately 20% [3]. Survival may
increase when patients are treated by multidisciplinary
teams, in centers with a large number of cases, with expe-
rience in the diagnosis and treatment of the disease [5, 6].
The Spanish Society of Medical Oncology (SEOM) is
aware of the importance of an early PC diagnosis and of an
adequate and comprehensive treatment by multidisci-
plinary teams. Therefore, SEOM has led the development
of a consensus with other specialties involved in the care of
these patients, including experts of recognized prestige
from 11 other scientific societies.
The aim of this study was to provide a consensus doc-
ument (PAN-TIME consensus), as a reference for the sci-
entific community, detailing the PC patient care process.
The consensus also recommends maximum times that
should not be exceeded in the different phases of the
diagnostic process or in the initiation of the different
treatment modalities. In addition, the consensus highlights
the importance of multidisciplinary management and
identifies opportunities for improving PC patients’ care.
Materials and methods
Design
The consensus method chosen was a modified Delphi
method following recommendations from RAND/UCLA
[7, 8]. A scientific committee was formed consisting of two
members of SEOM and one member of each of ten other
scientific societies: Spanish Society of Medical Radiology,
Spanish Society of Radiotherapy and Oncology, Spanish
Gastroenterology Association, Spanish Society of Ana-
tomic Pathology, Spanish Society of Internal Medicine,
Spanish Society of Family and Community Medicine,
Spanish Society of Primary Care Physicians, Spanish
Society of General and Family Physicians, Spanish Society
of Surgeons, Spanish Society of Surgical Oncology,
Spanish Society of Endocrinology and Nutrition.
Goals and consensus design were discussed face-to-face. A
bibliographic search was carried out and 40 items were written
in a consensual way. These items reflected the current situa-
tion of PC management and included recommendations on
aspects related to care process or that were not answered in the
scientific literature. Forty items were agreed on in six areas:
general aspects (4 items), pre-diagnosis (5 items), diagnosis
(12 items), treatment (12 items), follow-up (6 items), and
recommendations for future improvement (1 item).
Then the members of the expert panel were chosen who
were to evaluate these 40 items. The panelists were
selected by the scientific societies themselves taking into
account their experience, degree of knowledge, or rela-
tionship with PC in their professional field. The number of
panelists proposed was ten for each scientific society, with
the exception of primary care societies. Those societies
would have four representatives each so that the weight of
the specialty would be similar to that of the rest of the
participating societies.
Subsequently, the questionnaire was sent to the panelists
and was answered on line in two rounds. Agreement was
assessed with a nine-point ordinal scale (1 = full dis-
agreement, 9 = full agreement). Responses were grouped
into three categories: 1–3 = disagree; 4–6 = neither agree
nor disagree and; 7–9 = agree.
Statements that did not reach consensus were re-evalu-
ated in a second round, with the wording modified as they
were considered as misleading. Between rounds, panelists
were informed of the detailed distribution of responses
from the first analysis. Panelists who did not respond to the
first round were excluded from the following analysis.
Analysis
Consensus was reached if the median of the responses was
over 7 or below 3 and less than one-third of the panelists
voted outside the ranges and the interquartile range (IQR)
should be less than 4.
Results are shown in Tables 1, 2, 3, 4, 5 and 6 as number
of votes with median of the answers, IQR, degree of
agreement between panelists and final result regarding
agreement or disagreement for each item. The degree of
agreement indicates the percentage of panelists who voted
within the median range (1–3, 4–6, 7–9).
Items in which panellists did not reach consensus in the
first round (3 assertions) were re-evaluated in a second
round. Items’ wording was modified as it was considered
that agreement was not reached due to misleading wording.
Results
The final number of panelists was 97, with the following
representation: 10 experts each from the Spanish Society of
Medical Oncology, the Spanish Society of Medical Radi-
ology, the Spanish Society of Radiation Oncology, the
Spanish Association of Gastroenterology, Spanish Society
of Pathological Anatomy, of the Spanish Society of Inter-
nal Medicine and of the Spanish Association of Surgeons;
4 experts from the Spanish Society of Family and Com-
munity Medicine; 3 experts each from the Spanish Society
of Primary Care Physicians and the Spanish Society of
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General and Family Physicians; 9 experts from the Spanish
Society of Surgical Oncology, and 8 from the Spanish
Society of Endocrinology and Nutrition.
Of the 97 panelists selected, 8 did not respond in the first
round and were excluded from the following analysis. In
the second round there were two who did not respond.
There were thus 87 panelists whose responses were taken
into account by the scientific committee to reach
consensus.
Of the total of 40 items raised, there was consensus in
the agreement in 37 of them in the first round. Con-
sensus was reached in the agreement in two of the three
assertions that were questioned in the second round, so
after the two rounds agreement was reached in 39 of the
40 issues (97.5%) (Tables 1, 2, 3, 4, 5, 6). Table 7
summarizes the main recommendations agreed by the
panel of experts.
Discussion
PC is the fourth cancer with a higher mortality in Europe; it
has a poor prognosis and its survival has not improved in
the past decades [3]. For this reason, a document of prac-
tical recommendations elaborated by all the specialties
involved could be of great help to improve the care of
patients with PC.
With the ultimate goal of providing recommendations to
improve patients’ survival and quality of life, the scientific
committee grouped the items to discuss on four general






1. Pancreatic cancer has been classically associated with a certain nihilistic medical approach,
given the diagnostic difficulties and the limited therapeutic options
8 (6–8) 69.7 First round
agreement
2. Recently improvements in diagnostic techniques and new therapeutic options have improved the
overall care of the patient with PC. Thus, a call to end this perception should be desirable
7 (7–8) 78.3 Second round
agreement
3. The possibility of identifying combinations of symptoms with a higher positive predictive value
that may lead to suspicion of cancer, together with a continuous improvement in the capacity of
diagnostic and staging techniques are key objectives in the diagnostic phase
8 (7–8) 86.7 Second round
agreement
4. There are currently not enough data to perform systematic screening for PC in asymptomatic
patients. However, screening may be possible in some high-risk patients in the future
9 (7–9) 85.4 First round
agreement
IQR interquartile range






5. The primary care physician is usually the first to contact the patient with symptoms or signs due
to pancreatic cancer. It is crucial that PC physicians exercise a high degree of suspicion to achieve
a faster diagnosis of the disease
8 (6–9) 73.0 First round
agreement
6. A smaller proportion of patients with symptoms or signs due to pancreatic cancer are initially
diagnosed by gastroenterologists, surgeons or internists (without primary care) after obstructive
jaundice or acute pancreatitis, often with other symptoms like weight loss
8 (5–9) 71.9 First round
agreement
7. In general, the initial symptoms are nonspecific, not very striking or may also be due to other very
diverse, sometimes banal pathologies. Even in these suspected cases, the diagnosis is difficult and
it may take several months until the first consultation with the doctor and several more months
before the diagnosis is established
8 (8–9) 95.5 First round
agreement
8. The onset of diabetes without metabolic syndrome (especially in individuals older than 50 years),
non-specific gastrointestinal symptoms or involuntary weight loss are findings that may facilitate
suspicion of PC
8 (7–9) 79.8 First round
agreement
9. In primary care, the presence of jaundice in a patient aged over 40 years should be a reason to
refer the patient to the emergency room. In patients aged over 60 years, weight loss associated
with other gastrointestinal changes (especially abdominal pain and diarrhea), back pain or new-
onset diabetes should be a reason for referral to the specialist within 15 days





topics: (a) general aspects and pre-diagnosis; (b) diagnosis;
(c) treatment, and (d) monitoring.
General aspects and pre-diagnosis
The panelists agree that PC has been classically associ-
ated with a certain nihilistic medical approach, given the
diagnostic difficulties and the limited therapeutic options.
In this sense, PC mortality has not declined in recent
decades in Europe despite the fact that mortality from
other cancers has fallen by 26% in men and 20% in
women since 1990 [2]. The skepticism that could be
appreciated among Spanish physicians has also been
verified in studies in other countries, where surgery may
be aimed at only a small number of patients with PC [9].
Panelists make a call to end this perception and highlight
improvements in diagnostic techniques and new thera-
peutic options that can improve the overall care of the
patient with PC [5].
Panelists also agree that there are currently not enough
data to perform systematic screening for PC in asymp-
tomatic patients. However, screening may be possible in
some high-risk patients in the future. High-risk patients are
those with hereditary factors predisposing to the develop-
ment of the disease. However, only 5–10% of PC cases
were related to hereditary factors [3, 10]. The most fre-
quent mutation associated with PC is a mutation of breast
cancer gene 2 (BRCA2), which is also associated with
breast and ovarian cancer [11], although other mutations
are also associated with PC [3]. In addition, there are other
family syndromes associated with PC such as Peutz–
Jeghers syndrome, hereditary pancreatitis, hereditary non-
polyposis colorectal cancer (Lynch syndrome), and ataxia-
telangiectasia, among others [3].
Screening of some mutations in high-risk PC patients,
such as CDKN2A, BRCA1/2 or PALB2 mutations, has
been shown to be an effective strategy in detecting a
greater number of tumors in phases in which they are still






10. The standard diagnostic procedure should include first steps anamnesis, physical examination,
analytical and ultrasound tests
9 (8–9) 91.0 First round
agreement
11. When the ultrasound request specifies that it is intended to rule out pancreatic cancer, if it is not
diagnostic (for lack of visualization or for other reasons) there must be a protocol that leads
directly to the performance of an MCT scan
9 (8–9) 97.8 First round
agreement
12. The availability and speed to obtain complementary examinations, and specifically the
ultrasound, differ in different places, and the approach of the primary care physician must be
decided accordingly
8 (7–9) 79.8 First round
agreement
13. In primary care, if the availability of explorations is limited, when there is presence jaundice or
acute pain that causes suspicion of pancreatitis, the patient can be referred to the Emergency Unit
to perform diagnostic tests on an urgent basis
9 (8–9) 92.1 First round
agreement
14. When there is a substantial delay in the performance of ultrasound, while on primary care, the
request should specify a suspicion of pancreatic cancer, which should ensure a prompt scanning by
the diagnostic imaging service
8 (8–9) 94.4 First round
agreement
15. Ultrasound has a low sensitivity and detects tumors with a resolution of 2 cm so that most small
tumors are not detected. However, in general, it must be performed before moving towards other
tests since it does detect advanced tumors and/or with liver metastases
8 (6–9) 71.9 First round
agreement
16. Negative ultrasound results do not rule out pancreatic cancer. If the symptoms are sufficiently
indicative of this diagnosis, the patient should be referred to the specialist for a MCT scan
9 (8–9) 96.6 First round
agreement
17. Suspected cases while in primary care should be referred to a hospital with interdisciplinary
tumor committees with experience in the diagnosis and treatment of pancreatic cancer
9 (7–9) 82.0 First round
agreement
18. Regardless of how the diagnosis has been made (ultrasound or MCT) and in what type of unit it
is carried, every patient with pancreatic cancer should be given an MCT with a specific protocol to
assess the relationship of the tumor with the mesenteric vessels and to assess its resectability
9 (9–9) 97.8 First round
agreement
19. Upon suspicion of pancreatic cancer, the diagnostic study of the specialized unit should be
completed within 2 weeks
9 (8–9) 94.4 First round
agreement
20. Histological confirmation of the diagnosis should always be obtained, with the exception of
surgical cases in which histological examination will be performed with operative samples
8 (7–9) 85.4 First round
agreement
21. Each reference center should establish a multidisciplinary tumor committee (MDC) to which all
patients are presented





resectable [12, 13]. Screening of patients with a family
history of PC may also be useful, although the benefit is
more limited [13]. In practice, screening has been proposed
in people with two or more first-degree relatives with PC
with mutations associated with this disease or with a family
history with a high genetic load of PC (such as two affected
relatives, one of them first degree). Screening is also rec-
ommended in patients with inherited PC-associated syn-
dromes such as Peutz–Jeghers syndrome or hereditary
chronic pancreatitis associated with mutations in the
PRSS1 gene [10].
In most cases it is suggested to start screening at age 50,
except in patients with hereditary pancreatitis who are
advised to start at age 40.
Magnetic resonance imaging, echo-endoscopy or mag-
netic resonance cholangiopancreatography are proposed as
screening tests [10].
On the other hand, about 90% of PC cases are sporadic.
The risk factor most clearly related to this type of cancer is
tobacco. Other risk factors that have been described are
obesity, diabetes, excessive consumption of alcohol or red
meat, low fruit consumption, chronic pancreatitis, or
infection with Helicobacter pylori [3, 10]. These risk fac-
tors may be subject to change, which is a good opportunity
to design preventive measures.
Biomarkers are being investigated that could in the
future detect high-risk candidates for screening [4]. At the
moment, CA 19-9 is the only serum biomarker useful for
the diagnosis and follow-up of PC. As a diagnostic marker
it offers a sensitivity of 79–81% and a specificity of
80–90% in symptomatic patients. However, given its low
positive predictive value, its use as a biomarker for PC
screening in asymptomatic individuals is not indicated [5].
In patients diagnosed with PC, CA 19-9 can be used to






22. In all cases, the treatment to be applied (or, if appropriate, the conduct of new diagnostic
examinations) should be established by the MDC constituted in the center
9 (8–9) 91.0 First round agreement
23. The MDC should always include specialists in medical and radiotherapeutic oncology,
surgery, pathology, radiology, digestive apparatus, ecoendoscopy and nutrition/dietetics.
Optionally, each center may opt for the additional participation of specialists in critical care
(ICU/anesthesia), endocrinology, interventional radiology or other specialties
9 (7–9) 88.8 First round agreement
24. Centers that do not have MDC should refer the patient with a clear diagnosis or suspicion
of pancreatic cancer to a referral center that does
9 (8–9) 88.8 First round agreement
25. MDC decision-making sessions should be held at least weekly 9 (7–9) 79.8 First round agreement
26. Overall, the maximum time elapsed from the definitive diagnosis (including preliminary
staging) to the start of treatment should be 15 days–1 month
9 (8–9) 92.1 First round agreement
27. In approximately 20–30% of patients the decision of CMD may be surgical treatment
with curative intent. In such a case, the maximum time elapsed from decision to
intervention should be 4 weeks, but it should be attempted to reduce that time limit as much
as possible, ideally less than 15 days
9 (8–9) 94.4 First round agreement
28. Treatment of adjuvant chemotherapy should be initiated not before 3–4 weeks from the
intervention nor later than 6–8 weeks after the intervention, unless the patient’s recovery is
insufficient
9 (8–9) 88.8 First round agreement
29. In 70–80% of patients who are not candidates for curative intent surgery, treatment should
be applied or coordinated by medical oncology specialists. The maximum time elapsed
from the decision to the start of treatment should be 7 days for chemotherapy and 15 days
for chemoradiotherapy
8 (7–9) 84.3 First round agreement
30. Concomitant chemotherapy and radiotherapy treatment will be scheduled according to the
planning of the latter, but should not be delayed for more than 2 weeks
8 (7–9) 91.0 First round agreement
31. Some resection cases can be treated with preoperative chemotherapy or
chemoradiotherapy. In this case, the maximum time elapsed from the decision to the start of
treatment should be 4 weeks, but an attempt should be made to shorten the time limit as
much as possible, to be less than 15 days
8 (8–9) 93.3 First round agreement
32. The initiation of palliative chemotherapy should not be delayed for more than 7 days, if
the patient’s condition allows it
8 (7–9) 76.4 First round agreement
33. The treatment, both surgical and medical, should be performed in tertiary centers that
have experienced teams and access to all the complementary services that may be needed:
ICU, interventional vascular treatment, etc.




assess disease volume, correlates with stage and
resectability, and has prognostic value after resection of the
tumor [3, 5].
In the absence of good biomarkers, a high degree of
suspicion to reach a rapid diagnosis remains crucial,
especially among primary care physicians who are gener-
ally the first to treat the patient with symptoms that could
suggest PC.
Panelists also agree that the initial symptoms of PC are
nonspecific, not striking, or may be due to other patholo-
gies as well. For this reason, it is possible that the first
consultation with the specialist may be delayed by several
months. This undoubtedly contributes to the fact that most
patients (up to 80–85%) are not diagnosed until at the very
advanced stages of the disease, when the tumor has
metastasized in other organs [4].
PC symptoms depend on their location (head, tail or
body of the pancreas), as well as their size and stage [10].
About 60–70% are located in the head, 20–25% in the body
and the tail, and the remaining 10–20% affect the pancreas
diffusely [3].
Some common signs are jaundice, abdominal pain,
weight loss, steatorrhoea, or newly started diabetes. Non-
specific symptoms may also occur, such as abdominal pain,
nausea or vomiting [3, 10]. In this regard, the panel has
agreed on two specific recommendations:
• The onset of diabetes without metabolic syndrome
(especially in individuals older than 50 years), non-
specific gastrointestinal symptoms, or involuntary
weight loss, may facilitate suspicion of PC.
• In primary care, the presence of jaundice in a patient
aged over 40 years should be a reason to refer the
patient to the emergency room. In patients aged over
60 years, weight loss associated with other gastroin-
testinal changes (especially abdominal pain and diar-
rhea), back pain, or new-onset diabetes should be a
reason for referral to the specialist within 15 days.
Other classic symptoms of PC which may also arouse
suspicion of the physician are depression, migratory
thrombophlebitis (Trousseau’s syndrome), or the sign of
Courvoisier (palpable vesicle on the physical examination)
[3, 14].
Diagnostic
Multidetector or multislice computed tomography (MCT)
is the imaging technique of choice in the diagnosis and
staging of PC [15, 16]. Magnetic resonance imaging and
especially magnetic resonance cholangiopancreatography
are techniques that may also be useful, especially in cases
where MCT is inconclusive, such as in small tumors or






34. The follow-up to be performed must be defined by the MDC 8 (7–9) 85.4 First round agreement
35. In order to avoid repetitions and redundancies, each center must establish a consensual
protocol to define which specialties or units assume the follow-up of the different types of
patients and in the different phases
9 (8–9) 95.5 First round agreement
36. Each patient should have a specific physician responsible for his/her follow-up 9 (8–9) 92.1 First round agreement
37. If in palliative care, the patient should be treated by medical oncology specialists 7 (5–8) 57.8 No agreement
38. The medical oncology specialist will decide as to when the patient will receive
symptomatic palliative care within a palliative care program
9 (7–9) 87.6 First round agreement
39. Participation in the multidisciplinary tumor committee of an endocrinology / nutrition
specialist for screening and nutritional assessment, preoperative immunonutrition and
nutritional support, as well as its involvement in the follow-up of all patients for the control
of diabetes, pancreatic insufficiency and vitamin deficiencies, as appropriate
8 (6.5–9) 75.3 First round agreement
IQR interquartile range






40. It is recommended to create specialized diagnostic functional units with rapid circuits to
manage certain suspected PC defined according to the patient’s risk characteristics and
possible alarm signals




isointense tumors [15]. Panelists agree that ultrasound has a
low sensitivity for the detection of PC [15]. However,
being a non-invasive, readily available, and low-cost
technique, it is often the first diagnostic technique in
patients with jaundice or abdominal pain [15]. Therefore,
panelists consider that ultrasound should be part of the
initial diagnostic procedure along with anamnesis, physical
examination, and a blood test.
The following practical recommendations are given in
order to reduce the delay in performing the ultrasound and
the subsequent MCT:
• The ultrasound request should specify a suspicion of
PC, which should ensure a prompt scanning by the
diagnostic imaging service.
Table 7 Summary of recommendations
General and pre-diagnosis
1. PC has been classically associated with a certain nihilistic medical approach. In recent years, therapeutic improvements and new treatment
options justify leaving behind this skepticism in the face of more encouraging prospects
2. There are currently not enough data to support systematic screening for PC in asymptomatic patients. Since the initial symptoms are
nonspecific or not very noticeable, a high degree of suspicion, especially in primary care, is crucial for a faster diagnosis of the disease
3. The occurrence of diabetes, especially in patients aged over 50 years, without metabolic syndrome, or non-specific gastrointestinal changes
or involuntary weight loss may facilitate suspicion
4. In primary care, the presence of jaundice in a patient over 40 years old should be a reason to refer the patient to the emergency room. In
patients aged over 60 years, weight loss with other associated clinical problems (diarrhea, abdominal pain, nausea, vomiting, constipation,
or new-onset diabetes) should be a reason for referral to an specialist within 15 days
Diagnosis
5. The standard diagnostic procedure should include first steps anamnesis, physical examination, analytical and ultrasound tests
If there is a substantial delay in performing ultrasound scans, mention of the suspected PC in the application should determine an expedited
scanning
If ultrasound results are not diagnostic, there must be a protocol that leads directly to performance of a MCT scan
If the ultrasound is negative but symptoms are sufficiently indicative of PC, refer the patient to a specialist for the assessment of the case and
selection of the appropriate tests
6. Suspected cases while in primary care should be referred to a hospital with multidisciplinary tumor committees with experience in the
diagnosis and treatment of PC. Centers that do not have these committees should send the patient with diagnosis or clear suspicion of PC to
a referral center that does. The diagnostic study in such unit should be completed within 2 weeks
Treatment
7. The treatment to be applied (or alternatively new diagnostic tests) should always be established by a multidisciplinary tumor committee.
The committee should meet at least weekly
8. The multidisciplinary tumor committee should always include specialists in medical and radiotherapeutic oncology, surgery, pathology,
radiology, digestive system, ecoendoscopy and nutrition/dietetics. Optionally, each center may opt for additional participation of specialists
in critical care endocrinology, interventional radiology or other specialties
9. The maximum delay time to initiate treatment should not exceed the following deadlines:
Surgical treatment with curative intent: surgery should be performed in less than 15 days and no later than 4 weeks after tumor staging.
When adjuvant chemotherapy is needed, it is recommended to initiate it after 3–4 weeks from the intervention, but no later than
6–8 weeks after the intervention, unless there is an insufficient recovery of the patient
In patients who are not candidates for surgery, the maximum time from staging to initiation of chemotherapy should be 7 days, or 15 days
for chemoradiotherapy
In patients with borderline resectable tumors, preoperative chemotherapy or chemoradiotherapy should be started preferably in less than
15 days and no later than 4 weeks after staging
Palliative chemotherapy: no later than 7 days after staging
Follow-up
10. The type of follow-up to be performed should be defined by the multidisciplinary tumor committee. In order to avoid repetitions and
redundancies, each center must establish a consensual protocol to define which specialties or units assume the follow-up of the different
types of patients in the different phases. Each patient should have a specific physician responsible for their follow-up
11. Participation in the multidisciplinary tumor committee of an endocrinology / nutrition specialist for screening and nutritional assessment,
preoperative immunonutrition and nutritional support, as well as its involvement in the follow-up of all patients for the control of diabetes,
pancreatic insufficiency and vitamin deficiencies, as appropriate
Recommendations for the future
12. It is recommended to create specialized diagnostic functional units with rapid circuits to manage certain suspected PC defined according
to the patient’s risk characteristics and possible alarm signals
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• When there is clinical suspicion of PC and ultrasound is
not conclusive, there must be a protocol that leads
directly to MCT.
• If accessibility for explorations is limited (jaundice or
acute pain that causes suspected pancreatitis) the
patient may be referred to the emergency unit for
urgent diagnostic tests.
Panelists emphasize that a negative ultrasound does not
rule out PC and that if the symptoms are sufficiently
indicative, the patient should be referred to the specialist
for MCT test.
Although the panelists were not explicitly asked, the
scientific committee behind this consensus considers that
the maximum delay in performing an ultrasound from a
suspected PC should not exceed 10–15 days. Likewise,
after an inconclusive ultrasound, MCT should not be
delayed beyond 10–15 days.
The centralization of patients with PC in reference
centers, with more patients and more experience in the
treatment of pathology, improves their prognosis and sur-
vival [6, 17]. Similarly, panelists agree on the need for
reference centers that have multidisciplinary tumor com-
mittees, where patients with clear suspicion or with a
confirmed PC should be referred.
Panelists agree that multidisciplinary tumor committees
should include specialists in medical and radiotherapy
oncology, hepatobiliary surgery, pathology, radiology,
digestive tract, echo-endoscopy, and nutrition/dietetics.
Optionally, each center may opt for the additional partici-
pation of specialists in critical care, endocrinology, inter-
ventional radiology, or other specialties.
There is also consensus that in these units, a diagnostic
study should be completed within 2 weeks. This diagnostic
study usually includes hemogram, biochemistry, markers
such as CA 19-9, MCT, and biopsy. Regarding MCT, a
specific protocol is needed to assess the connection of the
tumor to mesenteric vessels and to be able to assess its
resectability. Pancreas protocols are not always equal
between centers but they usually include fine sections
(\3 mm) with a multiphase technique and a posterior
multiplanar reconstruction. Images are obtained in a pan-
creatic phase (40–50 s after contrast injection), as well as
in a portal venous phase (65–70 s after contrast injection)
[5, 15, 16, 18].
After these imaging studies, panelists consider that it is
mandatory to obtain a cytological or histological sample to
confirm the diagnosis of CP, except for surgical cases in
which histological examination is performed with opera-
tive samples [5]. The most recommendable technique for
sampling is biopsy or cytology by aspiration with fine
needle guided by echo-endoscopy [5]. This technique
offers better results and is safer than thin percutaneous
biopsy guided by MCT [5], although sometimes this
technique is necessary in more distal tumors. Samples can
also be obtained through endoscopic retrograde cholan-
giography [5], as in cases of obstructive jaundice, or by
ultrasound-guided puncture in case of liver metastases.
Treatment
Regarding therapeutic management, it is emphasized that
the multidisciplinary committee of tumors constituted in
the center should establish the treatment. In addition, it is
recommended that this committee should meet for deci-
sion-making at least once a week. The maximum period
elapsed from the definitive diagnosis and the beginning of
the treatment should be between 15 days and 1 month.
Resection with curative intent will be performed in
approximately 20% of patients. Eighty percent of patients
will be candidates for palliative treatment with
chemotherapy or chemoradiotherapy [3]. The panel has
established deadlines between the decision making process
and the initiation of treatment. These deadlines depend on
the type of treatment to be introduced and can be sum-
marized as follows:
• Surgical treatment with curative intent: surgery should
be performed in less than 15 days and no later than
4 weeks after tumor staging. When adjuvant
chemotherapy is needed, it is recommended to initiate
it after 3–4 weeks from the intervention, but no later
than 6–8 weeks after the intervention, unless there is an
insufficient recovery of the patient.
• In patients who are not candidates for surgery, the
maximum time from staging to initiation of chemother-
apy should be 7 days, or 15 days for chemoradiotherapy.
• In patients with borderline resectable tumors, preoper-
ative chemotherapy or chemoradiotherapy should be
started preferably in less than 15 days and no later than
4 weeks after staging.
• Palliative chemotherapy: no later than 7 days after
staging.
The panelist also agreed that treatment, both surgical
and medical, should be performed in tertiary centers that
have teams with experience in this pathology and have
access to all complementary services that may be neces-
sary: ICU, interventional vascular treatment, etc.
Follow-up
Finally, the last recommendations of the panelists address
the follow-up of the patients. It is recommended that each
center should establish a consensual protocol to define
which specialties or units assume the patient’s follow-up at
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each stage. This recommendation tries to avoid repetition
and redundancy in patient’s follow-up, since there may be
many physicians involved. However, each patient must
have a specific physician responsible for his or her follow-
up.
The panel did not discuss how this follow-up should be
carried out, probably because the patients and treatments are
heterogeneous and the type of follow-up is highly variable. In
patients who underwent surgical resection, US National
Comprehensive Cancer Network guidelines recommend a
clinical assessment by MCT and CA 19-9 levels every
3–6 months for 2 years and then every 6–12 months [5].
However, probably due to the poor prognosis of the disease,
there is no evidence that follow-up with MCT improves sur-
vival [3, 5, 19]. In general, follow-up should focus on symp-
tom control, nutrition, and psychosocial support [3].
The only item that was not consensual in the question-
naire was the one that suggested that in palliative treatment
specialists in medical oncology should treat the patient.
This point has been conflicting, probably because the pal-
liative treatment may include not only chemotherapy or
radiotherapy, which would involve medical and radio-
therapy oncology, but also palliative surgery, drainage,
prosthesis, pain treatment, etc. which would then include
surgeons, interventional radiologists, anesthetists, and
others. In this sense, the opinion of the scientific committee
is that in cancer treatment with palliative intent, the patient
should be treated by those specialists that the multidisci-
plinary tumor committee considers more appropriate in
each case according to the predominant clinic.
Limitations
This consensus suffers from the limitations inherent in the
Delphi methodology, specifically the selection of the panel
of experts and the limitation of the method to underline
particular evaluations of the experts. The panelists have
been selected by the scientific societies themselves, which
contributes to limit the selection bias of the participants. It
should be taken into account that this consensus is
strengthened by recommendations from all the specialties
involved in the management of PC. Moreover, the sponsors
of the consensus have not participated in any phase of
consensus development, nor in the analysis, interpretation
of results, or writing of the final document.
Conclusions
In summary, this consensus gives practical recommenda-
tions aimed at improving the overall management of the
patient with PC. The consensus emphasizes the importance
of the awareness of primary care physicians about possible
signs of alarm. It also recommends shortening the maxi-
mum time in the diagnostic process and initiation of
treatment. Finally, it highlights the importance of central-
izing management in reference centers with specialized
multidisciplinary units.
The work between cooperative groups of different spe-
cialties involved in this pathology can improve the
approach to this complex disease, including its diagnostic
methods, treatments with curative intention, disseminated
disease, support treatment, and nutrition.
The present consensus can facilitate the early diagnosis
of patients and improve the surgical and medical-palliative
possibilities of the patients affected by this complex
pathology.
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